Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (21-30 of 468) with videos related to

Pageof 47
Sort By:
JAMA Oncology|February 26, 2016
Response Rate as an Approval End Point in Oncology: Back to the FutureGideon M Blumenthal, Richard Pazdur
Seminars in Oncology|March 13, 2016
Looking to the future in an unprecedented time for cancer drug developmentPaul G Kluetz, Richard Pazdur
The New England Journal of Medicine|June 1, 2012
Pathological complete response and accelerated drug approval in early breast cancerTatiana M Prowell, Richard Pazdur
Oncology (Williston Park, N.Y.)|June 25, 2004
Progress in the development of novel treatments for colorectal cancerPaulo M Hoff, Richard Pazdur
Clinical Colorectal Cancer|November 28, 2002
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancerIsagani M Chico, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed DrugGautam U Mehta, Richard Pazdur
The New England Journal of Medicine|December 15, 2021
The Wild West of Checkpoint Inhibitor DevelopmentJulia A Beaver, Richard Pazdur
Nature Reviews. Clinical Oncology|February 13, 2020
Approvals in 2019: international review and a new agnostic molecular entityHarpreet Singh, Gideon Blumenthal, Richard Pazdur
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
JAMA Internal Medicine|August 8, 2017
Setting the Record Straight on FDA Approvals in OncologyGideon Blumenthal, Geoffrey Kim, Richard Pazdur
Pageof 47

Showing results (21-30 of 468) with videos related to

Sort By:
Pageof 47
JAMA Oncology|February 26, 2016
Response Rate as an Approval End Point in Oncology: Back to the FutureGideon M Blumenthal, Richard Pazdur
Seminars in Oncology|March 13, 2016
Looking to the future in an unprecedented time for cancer drug developmentPaul G Kluetz, Richard Pazdur
The New England Journal of Medicine|June 1, 2012
Pathological complete response and accelerated drug approval in early breast cancerTatiana M Prowell, Richard Pazdur
Oncology (Williston Park, N.Y.)|June 25, 2004
Progress in the development of novel treatments for colorectal cancerPaulo M Hoff, Richard Pazdur
Clinical Colorectal Cancer|November 28, 2002
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancerIsagani M Chico, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed DrugGautam U Mehta, Richard Pazdur
The New England Journal of Medicine|December 15, 2021
The Wild West of Checkpoint Inhibitor DevelopmentJulia A Beaver, Richard Pazdur
Nature Reviews. Clinical Oncology|February 13, 2020
Approvals in 2019: international review and a new agnostic molecular entityHarpreet Singh, Gideon Blumenthal, Richard Pazdur
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
JAMA Internal Medicine|August 8, 2017
Setting the Record Straight on FDA Approvals in OncologyGideon Blumenthal, Geoffrey Kim, Richard Pazdur
Pageof 47